Summary.-Fifty-six patients with disseminated malignant melanoma were randomly allocated to two treatment groups. The first group C received combination chemotherapy consisting of DTIC and ICRF 159. The second group (C + I) received the same chemotherapy but were also immunized with 2 x 107 irradiated allogeneic melanoma cells mixed with 50 ,ug of percutaneous BCG. The survival rates in both treatment groups C and (C + I) were not significantly different, and only minor enhancement of the chemotherapy was found in the (C + 1) group. A similar pattern of tissue response was observed in both groups: lymph node, skin and, to some extent liver metastases, respond better than other sites.
THE CURRENT treatments for disseminated malignant melanoma are unsatisfactory. Analysis of the patients followed up at the Westminster Hospital in the pretrial period showed that the 2-and 5-year survivals for Stage IIb were 51°/ and 200% respectively. The one-year survival for Stage III was only 1000. These disappointing results are similar to the experience of others (Bodenham, 1968; Johnson and Jacobs, 1971; Luce, 1972) . The most widely studied drug in disseminated malignant melanoma is DTIC, which has induced an objective regression rate in around 20% of cases in a number of series (summarized in Comis and Carter, 1974) . These regressions are commonly short-lived and numerous attempts have been made to improve the success rate by combining DTIC with other agents. So far no marked enhancement of the DTIC effect has been reported (Comis and Carter, 1974) . However, animal experiments have shown that ICRF 159 can enhance the cytotoxic effect of DTIC (Wasserman et al., 1973) . ICRF 159 has not been reported in combination with DTIC in malignant melanoma. This study was designed both to assess the efficiency of DTIC and ICRF 159 as a combination in treating melanoma and to see whether specific active immunotherapy was a useful adjuvant to the chemotherapy. Immunization of melanoma patients with their own irradiated tumour cells has been shown to stimulate both cytotoxic antibody (Ikonopisov et al., 1970) and cytotoxic lymphocytes (Currie, Lejeune and Fairley, 1971) . More recent studies have reported that both the combination of chemotherapy with non-specific immunotherapy (Gutterman et al., 1973) and specific active immunotherapy with allogeneic melanoma cells (Currie and McElwain, 1975) can improve the response rates in malignant melanoma. In this study the specific active immunotherapy was based on the work of Currie and McElwain (1975) .
MATERIALS AND METHODS
Patients.-The study commenced in January 1974. The staging of malignant melanoma used is the Westminster Hospital Classification (Butterworth et al., 1974 A trend was observed for both treatment groups in that lymph node and skin deposits were more responsive to treatment than visceral deposits. The numbers are, however, too small to make significant statements, but the results are consistent with those of other authors (Wagner, Ramirez and Weiss, 1971; Luce, 1972; Einhorn et al., 1974) . Immunotherapy appears to increase the response rate at certain sites and it should be noted that the (C + I) group contained more patients (13/19) with visceral involvement than group C (7/17). It is possible that, if immunotherapy was only exerting a minor effect, this might only be detected in patients with disease at more responsive sites. The numbers of patients with disease limited to skini and lymph node are small but in group (C + I) 4/6 (66%o) responded when compared with 4/10 (40 0%) in group C.
The results show that the responses in the combined groups C and (C + I) of 36% is lower thain the 57% response rate reported by Currie and McElwain (1975) . Their group of patients were treated with DTIC (at the same dosage as used here) plus vincristine and all their patients received immunotherapy with melanoma cells plus BCCG. They had no control group of chemotherapy alone. However, when their series is analysed by the tissue sites which responded to the therapy, 12/17 of the responses were in skin and lymph node and only 5 in visceral deposits. The similarity in the pattern of responses in both groups in this study and in Currie and McElwain's (1975) series implies that the major active agent in both protocols is the chemotherapy (probably mainly DTIC). As suggested above, the immunotherapy used may play a minor role by increasing the response of certain sites to chemotherapy, but it has not altered the survival rate. There is evidence that non-specific immunotherapy with BCG can enhance the effect of DTIC (Gutterman et al., 1973 and 1974 The addition of ICRF 159 to DTIC did not increase the toxicity at the dosage used. However, at this relatively low dose of DTIC the response rate has been comparable to that in a number of other series using higher doses of DTIC (Comis and Carter, 1974) . The major toxicity encountered was nausea and vomiting on the first 2 days of each course. This was attributed to the DTIC. A further study of this drug combination using dose escalation will be required to show whether or not ICRF 159 can enhance the response rate to DTIC.
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